Pharmaceutisch weekblad

, Volume 3, Issue 1, pp 1021–1041 | Cite as

Multiple dopamine receptors: fact, fiction or confusion?

  • A. S. Horn
  • M. G. P. Feenstra
  • C. J. Grol
  • H. Rollema
  • J. C. Van Oene
  • B. H. C. Westerink
Review Articles


A critical review of the various theories postulating the existence of multiple dopamine (DA) receptors is presented. After a summary of the pharmacological methods used in measuring dopaminergic agonist and antagonist activities the evidence for postsynaptic, presynaptic, D-I, D-2, D-3, DA-1, DA-2, DAe and Dai receptors is examined. The possible clinical significance of these various theories is also briefly discussed.


Substantia Nigra Adenylate Cyclase Apomorphine Sulpiride Kainic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aghajanian, G. K., andB. S. Bunney (1974) In:Frontiers of Neurology and Neuroscience Research (Seeman, P., Ed.). University of Toronto Press, Toronto, 4–11;Ibidem (1977)Naunyn-Schmiedebergs Arch. Pharmacol. 297, 1–7.Google Scholar
  2. Ahn, A. S., S. C. Feldman andM. H. Makman (1979)Brain Res. 166, 422–425.PubMedCrossRefGoogle Scholar
  3. ålander, T., N. E. Anden andM. Grabowska-Anden (1980)Naunyn-Schmiedebergs Arch. Pharmacol. 312, 145–150.PubMedCrossRefGoogle Scholar
  4. Anden, N. E., T. Magnusson andG. Stock (1973)Naunyn-Schmiedebergs Arch. Pharmacol. 278, 363–372.PubMedCrossRefGoogle Scholar
  5. Arbilla, S., andS. Z. Langer (1978)Nature 271, 559–561.PubMedCrossRefGoogle Scholar
  6. Argiolas, A., F. Fadda, M. R. Melis andG. L. Gessa (1979)Life Sciences 24, 2279–2284.PubMedCrossRefGoogle Scholar
  7. Azuma, H., andN. Oshino (1980)Japan. J. Pharmacol. 30, 629–639.CrossRefGoogle Scholar
  8. Bach, N. J., E.C. Kornfeld, N. D. Jones, M. O. Chaney, D. E. Dorman, J. W. Paschal, J. A. Clemens andE. B. Smalstig (1980)J. Med. Chem. 23, 481–491.PubMedCrossRefGoogle Scholar
  9. Baring, M. D., J. R. Walters andN. Eng (1980)Brain Res. 181, 214–218.PubMedCrossRefGoogle Scholar
  10. Berde, B. (1980) In:Ergot Compounds and Brain Function. Advances in Biochemical Psychopharmacalogy, Vol. 23 (Goldstein, M., D. B. Calne, A. Lieberman andM. O. Thorner, Eds.). Raven Press, New York, 3–23.Google Scholar
  11. Bockaert, J., J. Premont, J. Glowinski, A. M. Thierry andJ. P. Tassin (1976)Brain Res. 107, 303–315.CrossRefGoogle Scholar
  12. Brown, E. M., R. J. Carroll andG. D. Auerbach (1977)Proc. Natl. Acad. Sci. USA 74, 4210–4213.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Brown, E. M., M. F. Attie, S. Reen, D. G. Gardner, J. Kebabian andG. D. Auerbach (1980)Mol. Pharmacol. 18, 335–340.PubMedGoogle Scholar
  14. Broxterman, H. J., C. F. M. Van Valkenburg andE. L. Noach (1980) In:Central Neurotransmitter Turnover (Pycock, C. J., andP. V. Taverner, Eds.). Croom Helm, London, 143–148.Google Scholar
  15. Bunney, B. S. (1979) In:The Neurobiology of Dopamine, 417–452.Google Scholar
  16. Bunney, B. S., andG. K. Aghajanian (1976)Science 192, 391–393;Ibidem (1978)Naunyn-Schmiedebergs Arch. Pharmacol. 304, 255–261.PubMedCrossRefGoogle Scholar
  17. Bunney, B. S., andA. A. Grace (1978)Life Sciences 23, 1715–1728.PubMedCrossRefGoogle Scholar
  18. Bunney, B. S., G. K. Aghajanian andR. A. Roth (1973)Nature 245, 123–125.Google Scholar
  19. Burt, D. R. (1978) In:Neurotransmitter Receptor Binding (Yamamura, H. I., S. J. Enna andM. J. Kuhar, Eds.). Raven Press, New York, 41–55.Google Scholar
  20. Calne, D. B. (1980)Trends in Pharmacol. Sci. 1, 412–414.CrossRefGoogle Scholar
  21. Calne, D. B., T. N. Chase andA. Barbeau (Eds.) (1975)Advances in Neurology, Vol. 9. Raven Press, New York.Google Scholar
  22. Cannon, J. G. (1975) In:Advances in Neurology, Vol. 9 (Calne, D. B., T. N. Chase andA. Barbeau, Eds.). Raven Press, New York, 177–183.Google Scholar
  23. Carlsson, A. (1975) In:Pre- and Postsynaptic Receptors (Usdin, E., andW. E. Bunney, Eds.). Marcel Dekker, New York, 49–65.Google Scholar
  24. Carlsson, A., andM. Lindqvist (1963)Acta Pharmacol. Toxicol. 20, 140–144.CrossRefGoogle Scholar
  25. Carlsson, A., M. Lindqvist, T. Magnusson andB. Waldeck (1958)Science 127, 471.PubMedCrossRefGoogle Scholar
  26. Carlsson, A., J. Engel, U. Strömbom, T. H. Svensson andB. Waldeck (1974)Naunyn-Schmiedebergs Arch. Pharmacol. 283, 117–128.PubMedCrossRefGoogle Scholar
  27. Carlsson, A., W. Kehr andM. Lindqvist (1977)J. Neural Transm. 40, 99–113.PubMedCrossRefGoogle Scholar
  28. Chan, C. C., andS. Kalsner (1979)Brit. J. Pharmacol. 67, 401–407.CrossRefGoogle Scholar
  29. Christiansen, J., andR. F. Squires, (1974)J. Pharm. Pharmacol. 26, 367–369.PubMedCrossRefGoogle Scholar
  30. Cools, A. R. (1981)Trends in Pharmacol. Sci. 2, 178–183.CrossRefGoogle Scholar
  31. Cools, A. R., andJ. M. van Rossum (1976)Psychopharmacologia 45, 243–254;Ibidem (1980)Life Sci. 27, 1237–1253.PubMedCrossRefGoogle Scholar
  32. Corrodi, H., L. O. Farnebo, K. Fuxe andB. Hamberger (1975)European J. Pharmacol. 30, 172–181.CrossRefGoogle Scholar
  33. Costall, B., andN. J. Naylor (1976)J. Pharm. Pharmacol. 28, 592–595;Ibidem (1979) In:The Neurobiology of Dopamine, 555–576.PubMedCrossRefGoogle Scholar
  34. Costall, B., R. J. Naylor andR. T. Owen (1978)European J. Pharmacol. 49, 407–413.CrossRefGoogle Scholar
  35. Costall, B., R. J. Naylor andV. Nohria (1980)Neuroscience Lett. Supp. 5, S462.Google Scholar
  36. Coyle, J. T., andR. Schwarcz (1976)Nature 263, 244–246.PubMedCrossRefGoogle Scholar
  37. Creese, I., andD. R. Sibley (1979)Comm. in Psychopharmacol. 3., 385–395.Google Scholar
  38. Creese, I., andS. H. Snyder (1979)European J. Pharmacol. 56, 277–281.CrossRefGoogle Scholar
  39. Creese, I., D. R. Burt andS. H. Snyder (1975)Life Sci. 17, 993–1002;Ibidem (1976)Science 192, 481–483.CrossRefGoogle Scholar
  40. Creese, I., T. Prosser andS. H. Snyder (1978)Life Sci. 23, 495–500.PubMedCrossRefGoogle Scholar
  41. Creese, I., K. Stewart andS. H. Snyder (1979a)European J. Pharmacol. 60, 55–66.CrossRefGoogle Scholar
  42. Creese, I., T. Usdin andS. H. Snyder (1979b)Nature 278, 577–578.PubMedCrossRefGoogle Scholar
  43. Cuatrecasas, P. (1974)Ann. Rev. Biochem. 43, 169–214.PubMedCrossRefGoogle Scholar
  44. Dandiya, P. C., H. L. Sharma, S. K. Patni andR. S. Ghambhir (1975)Experientia 31, 1441–1443.PubMedCrossRefGoogle Scholar
  45. Da Prada, M., A. Saner, W. P. Burkard, G. Bartholini andA. Pletscher (1975)Brain Res. 95, 67–73.CrossRefGoogle Scholar
  46. Di Chiara, G., M. L. Porceddu, L. Vargiu, A. Argiolas andG. L. Gessa (1976)Nature 264, 564–567.PubMedCrossRefGoogle Scholar
  47. Di Chiara, G., G. P. Mereu, L. Vargiu, M. L. Porceddu.A. Mulas, M. Trabucchi andP. F. Spano (1977a) In:Advances in Biochemical Psychopharmacology, Vol. 16 (Costa, E., andG. J. Gessa, Eds.). Raven Press, New York, 477–481.Google Scholar
  48. Di Chiara, G., M. L. Porceddu, P. F. Spano andG. L. Gessa (1977b)Brain Res. 130, 374–382.PubMedCrossRefGoogle Scholar
  49. Di Chiara, G., G. P. Mereu, L. Vargiu, M. L. Porceddu, A. Mulas, M. Trabucchi andP. F. Spano (1978) In:Dopamine. Advances in Biochemical Psychopharmacology, Vol. 19 (Roberts, P. J., G. N. Woodruff andL. L. Iversen, Eds.). Raven Press, New York, 275–292.Google Scholar
  50. Eccles, J. C. (1964)The Physiology of Synapses. Springer-Verlag, Berlin.CrossRefGoogle Scholar
  51. Euvrard, C., J. Premont, C. Oberlander, J. R. Boissier andJ. Bockaert (1979)Naunyn-Schmiedebergs Arch. Pharmacol. 309, 241–245.PubMedCrossRefGoogle Scholar
  52. Everitt, B. J., andK. Fuxe (1977)Neurosci. Lett. 4, 209–213.PubMedCrossRefGoogle Scholar
  53. Farnebo, L. O., andB. Hamberger (1971)Acta Physiol. Scand. 84, Suppl. 371, 35–44.CrossRefGoogle Scholar
  54. Fields, J. Z., T. D. Reisine andH. I. Yamamura (1978)Life Sciences 23, 569–574.PubMedCrossRefGoogle Scholar
  55. Fuller, R. W., J. A. Clemens, E. C. Kornfeld, H. D. Snoddy, E. B. Smalstig andN. J. Bach (1979)Life Sciences 24, 375–382.PubMedCrossRefGoogle Scholar
  56. Furchgott, R. F. (1972) In:Catecholamines. Handbook of Experimental Pharmacology, Vol. XXXIII (Blaschko, H., andE. Muscholl, Eds.). Springer-Verlag, Berlin, 283–335.Google Scholar
  57. Garcia Munoz, M., N. M. Nicolaou, I. F. Tulloch, A. Wright andG. W. Arbuthnott (1977)Nature 265, 364–365.CrossRefGoogle Scholar
  58. Gibson, A., andM. Samini (1979) In:Catecholamines: Basic and Clinical Frontiers, Vol. 1 (Usdin, E., I. Kopin andJ. Baschas, Eds.). Pergamon Press, New York, 417.CrossRefGoogle Scholar
  59. Gilman, A. G., L. S. Goodman andA. Gilman (Eds.) (1980)The Pharmacological Basis of Therapeutics, 6th ed. McMillan, New York, 403.Google Scholar
  60. Glowinski, J., A. Cheramy andM. F. Giorguieff (1979) In:The Neurobiology of Dopamine, 199–216.Google Scholar
  61. Goldberg, L. I. (1979) In:The Neurobiology of Dopamine, 541–551.Google Scholar
  62. Goldberg, L. I., andJ. D. Kohli (1979)Comm. in Psychopharmacol. 3, 447–456.Google Scholar
  63. Goldberg, L. I., P. H. Volkman andJ. D. Kohli (1978)Ann. Rev. Pharmacol. Toxicol. 18, 57–79.CrossRefGoogle Scholar
  64. Goldstein, M., J. Y. Lew, F. Hata andA. Lieberman (1978)Gerontology 24 (Suppl. 1), 76–85.PubMedGoogle Scholar
  65. Govoni, S., V. R. Olgiati, M. Trabucchi, L. Gavan, E. Stefanini andP. F. Spano (1978)Neurosci. Lett. 8, 207–210.PubMedCrossRefGoogle Scholar
  66. Gudelsky, G. A., andK. E. Moore (1976)J. Neural Transm. 38, 95–105.PubMedCrossRefGoogle Scholar
  67. Henn, F. A., andS. W. Henn (1980)Progr. Neurobiol. 15, 1–17.CrossRefGoogle Scholar
  68. Henn, F. A., D. Anderson andA. Sellström (1977)Nature 266, 637–638.PubMedCrossRefGoogle Scholar
  69. Hicks, P. E., andJ. G. Cannon (1979)J. Pharm. Pharmacol. 31, 494–496.PubMedCrossRefGoogle Scholar
  70. Hirschorn, J. D., andE. L. Gardner (1980)European J. Pharmacol. 62, 123–124.CrossRefGoogle Scholar
  71. Hoffman, F. M. (1979)J. Biol. Chem. 25, 255–258.Google Scholar
  72. Horn, A. S. (1979) In:The Neurobiology of Dopamine, 217–235.Google Scholar
  73. Horn, A. S., J. Korf andB. H. C. Westerink (Eds.) (1979)The Neurobiology of Dopamine. Academic Press, London.Google Scholar
  74. Hutt, C. S., S. R. Snider andS. Fahn (1977)Neurology 27, 505–510.CrossRefGoogle Scholar
  75. Hyttel, J. (1978)Life Sciences 23, 551–556.PubMedCrossRefGoogle Scholar
  76. Iversen, L. L. (1975)Science 188, 1084–1089.PubMedCrossRefGoogle Scholar
  77. Iversen, L. L., N. J. Rogawski andR. J. Miller (1976)Molec. Pharmacol. 12, 251–262.Google Scholar
  78. Jain, P. C., andN. Kumar (1977) In:Progress in Drug Research, Vol. 21 (Jucker, E., Ed.). Birkhäuser Verlag, Basle, 409–465.Google Scholar
  79. Kalsner, S., andC. C. Chan (1980)Can. J. Physiol. Pharmacol. 58, 504–512.PubMedCrossRefGoogle Scholar
  80. Kebabian, J. W., andD. B. Calne (1979)Nature 277, 93–96.PubMedCrossRefGoogle Scholar
  81. Kebabian, J. W., andP. Greengard (1971)Science 174, 1346–1349.PubMedCrossRefGoogle Scholar
  82. Kebabian, J. W., G. L. Petzold andP. Greengard (1972)Proc. Natl. Acad. Sci. USA 69, 2145–2149.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Kehr, W., A. Carlsson, M. Lindqvist, T. Magnusson andC. Atack (1972)J. Pharm. Pharmacol. 24, 744–747.PubMedCrossRefGoogle Scholar
  84. Kehr, W., A. Carlsson andM. Lindqvist (1977)Naunyn-Schmiedebergs Arch. Pharmacol. 297, 111–117.PubMedCrossRefGoogle Scholar
  85. Kondo, Y., andK. Iwatsubo (1980)Brain Res. 181, 237–240.PubMedCrossRefGoogle Scholar
  86. Krnjevic, K. (1974)Physiol. Rev. 45, 419–540.Google Scholar
  87. Laduron, P. (1980)Trends in Pharmacol. Sci. 1, 471–474.CrossRefGoogle Scholar
  88. Langer, S. Z. (1974)Biochem. Pharmacol. 23, 1793–1800.PubMedCrossRefGoogle Scholar
  89. Lees, A. J., C. M. Lander andG. M. Stern (1978)Lancet II, 1205.CrossRefGoogle Scholar
  90. Leysen, J. E. (1979)Comm. in Psychopharmacol. 3, 397–410;Ibidem (1980) In:Advances in Biochemical Psychopharmacology, Vol. 24 (Cattabeni, F.,et al., Eds.). Raven Press, New York, 123–132.Google Scholar
  91. Leysen, J. E., andW. Gommeren (1981)J. Neurochem. 36, 201–219.PubMedCrossRefGoogle Scholar
  92. Leysen, J. E., andP. Laduron (1977)Life Sciences 20, 281–288.PubMedCrossRefGoogle Scholar
  93. Leysen, J. E., W. Gommeren andP. M. Laduron (1978a)Biochem. Pharmacol. 27, 307–316.PubMedCrossRefGoogle Scholar
  94. Leysen, J. E., C. J. E. Niemegeers, J. P. Tollenaere andP. M. Laduron (1978b)Nature 272, 168–171.PubMedCrossRefGoogle Scholar
  95. Libet, B. (1979) In:The Neurobiology of Dopamine, 453–474.Google Scholar
  96. Lichtensteiger, W.: (1979) In:The Neurobiology of Dopamine, 491–521.Google Scholar
  97. Lindvall, O. (1979) In:The Neurobiology of Dopamine, 319–342.Google Scholar
  98. List, S., M. Titeler andP. Seeman (1980)Biochem. Pharmacol. 29, 1621–1622.PubMedCrossRefGoogle Scholar
  99. Marchais, D., andJ. Bockaert (1980)Biochem. Pharmacol. 29, 1331–1336.PubMedCrossRefGoogle Scholar
  100. Marek, K. L., andR. H. Roth (1980)European J. Pharmacol. 62, 137–146.CrossRefGoogle Scholar
  101. Martres, M. P., J. Costentin, M. Baudry, H. Marcais, P. Protais andJ. C. Schwartz (1977)Brain Res. 136, 319–337.PubMedCrossRefGoogle Scholar
  102. Mcgeer, P. L., andE. G. Mcgeer (1979) In:The Neurobiology of Dopamine, 381–392.Google Scholar
  103. Meltzer, H. Y. (1980)Schizophrenia Bull. 6, 456–475.CrossRefGoogle Scholar
  104. Miller, R. J., andJ. Mcdermed (1979) In:The Neurobiology of Dopamine, 159–177.Google Scholar
  105. Miller, R. J., A. S. Horn, L. L. Iversen andR. Pinder (1974)Nature 250, 238–241.PubMedCrossRefGoogle Scholar
  106. Mulder, A. H., J. C. Stoof andA. S. Horn (1980)European J. Pharmacol. 67, 147–150.CrossRefGoogle Scholar
  107. Nadler, J. V. (1979)Life Sciences 24, 289–300.PubMedCrossRefGoogle Scholar
  108. Nagy, J. I., T. Lee, P. Seeman andH. C. Fibiger (1978)Nature 274, 278–281.PubMedCrossRefGoogle Scholar
  109. Nishikori, K., O. Noshiro, K. Sano andH. Maeno (1980)J. Biol. Chem. 255, 10909–10915.PubMedGoogle Scholar
  110. Nueten, J. M. Van, C. Ennis, L. Helsen, P. M. Laduron andP. A. J. Janssen (1978)Life Sciences 23, 453–458.PubMedCrossRefGoogle Scholar
  111. Pagnini, G., F. Camanni, A. Crispino andP. Portaleone (1978)J. Pharm. Pharmacol. 30, 92–95.PubMedCrossRefGoogle Scholar
  112. Palmer, G. C., andA. A. Manian (1976)Biochem. Pharmacol. 25, 63–71.PubMedCrossRefGoogle Scholar
  113. Peroutka, S. J., andS. H. Snyder (1980)Am. J. Psychiatry 137, 1518–1522.PubMedCrossRefGoogle Scholar
  114. Phillipson, O. T., andA. S. Horn (1976)Nature 261, 418–420.PubMedCrossRefGoogle Scholar
  115. Phillipson, O. T., P. C. Emson, A. S. Horn andT. Jessell (1977)Brain Res. 136, 45–58.PubMedCrossRefGoogle Scholar
  116. Price, P., J. D. Parkes andC. D. Marsden (1978)Lancet II, 1106.CrossRefGoogle Scholar
  117. Quik, M., andL. L. Iversen (1979)European J. Pharmacol. 56, 323–330.CrossRefGoogle Scholar
  118. Raiteri, M., A. M. Cervoni, R. Del Carmine andG. Levi (1978)Nature 274, 706–708.PubMedCrossRefGoogle Scholar
  119. Reisine, T. D., J. I. Nagy, H. C. Fibiger andH. I. Yamamura (1979)Brain. Res. 169, 209–214.PubMedCrossRefGoogle Scholar
  120. Rodbell, M., M. C. Lin, Y. Solomon, C. Londos, J. P. Harwood, B. R. Martin, M. Rendell andM. Berman (1975)Advan. Cyclic Nucleotide Res. 5, 3–29.Google Scholar
  121. Rosenfeld, M. R., M. H. Makman andM. Goldstein (1980)European J. Pharmacol. 68, 65–68.CrossRefGoogle Scholar
  122. Ruffolo, R. R., E. L. Rosing andJ. E. Waddell (1979)J. Pharmacol. Exp. Therap. 209, 429–436.Google Scholar
  123. Saiani, L., M. Trabucchi, G. C. Tonon andP. F. Spano (1979)Neurosci. Lett. 14, 31–36.PubMedCrossRefGoogle Scholar
  124. Sano, K., K. Nishikori, O. Noshiro andH. Maeno (1979)Arch. Biochem. Biophys. 197, 285–293.PubMedCrossRefGoogle Scholar
  125. Scatton, B., andP. Worms (1979)J. Pharm. Pharmacol. 31, 861–863.PubMedCrossRefGoogle Scholar
  126. Scatton, B., J. Dedek andJ. Korf (1977)Brain Res. 135, 374–377.PubMedCrossRefGoogle Scholar
  127. Schachter, M., P. Bédard, A. G. Debono, P. Jenner, C. D. Marsden, P. Price, J. D. Parkes, J. Keenan, B. Smith, J. Rosenthaler, R. Horowski andR. Dorow (1980)Nature 286, 157–159.PubMedCrossRefGoogle Scholar
  128. Schally, A. V., T. W. Redding, A. Arimura, A. Dupont andG. L. Linthicum (1977)Endocrinology 100, 681–691.PubMedCrossRefGoogle Scholar
  129. Schmidt, M., andJ. L. Imbs (1980)J. Cardiovasc. Pharmacol. 2, 595–605.PubMedCrossRefGoogle Scholar
  130. Schwarcz, R., I. Creese, J. T. Coyle andS. H. Snyder (1978)Nature 271, 766–768.PubMedCrossRefGoogle Scholar
  131. Seeman, P. (1977)Biochem. Pharmacol. 26, 1741–1748.PubMedCrossRefGoogle Scholar
  132. Seeman, P., M. Chau-Wong, J. Tedesco andK. Wong (1975)Proc. Natl. Acad. Sci. USA 72, 4376–4380.PubMedPubMedCentralCrossRefGoogle Scholar
  133. Seeman, P., T. Lee, M. Chau-Wong, J. Tedesco andK. Wong (1976)Proc. Natl. Acad. Sci. USA 73, 4354–4358.PubMedPubMedCentralCrossRefGoogle Scholar
  134. Sethy, V. H. (1979)European J. Pharmacol. 60, 397–398.CrossRefGoogle Scholar
  135. Siggins, S. R. (1978) In:Psychopharmacology: A generation of progress (Lipton, M. A., A. Dimascio andK. F. Killam, Eds.). Raven Press, New York, 143–157.Google Scholar
  136. Skirboll, L. R., A. A. Grace andB. S. Bunney (1979)Science 206, 80–82.PubMedCrossRefGoogle Scholar
  137. Snider, S. R., C. Hutt, B. Stein, A. L. N. Prasad andS. Fahn (1976)J. Pharm. Pharmacol. 28, 563–566.PubMedCrossRefGoogle Scholar
  138. Snyder, S. H., andR. R. Goodman (1980)J. Neurochem. 35, 5–15.PubMedCrossRefGoogle Scholar
  139. Sokoloff, P., M. Martres andJ. C. Schwartz (1980)Nature 288, 283–286.PubMedCrossRefGoogle Scholar
  140. Spano, P. F., L. Saiani, M. Memo andM. Trabucchi (1980) In:Advances in Biochemical Psychopharmacology, Vol. 23 (Goldstein, M., D. B. Calne, A. Lieberman andM. O. Thorner, Eds.). Raven Press, New York, 95–102.Google Scholar
  141. Starke, K., H. D. Taube andE. Borowski (1977)Biochem. Pharmacol. 26, 259–268.PubMedCrossRefGoogle Scholar
  142. Starke, K., W. Reimann, A. Zumstein andG. Herting (1978)Naunyn-Schmiedebergs Arch. Pharmacol. 305, 27–36.PubMedCrossRefGoogle Scholar
  143. Stoof, J. C., A. S. Horn andA. H. Mulder (1980)Brain Res. 196, 276–281.PubMedCrossRefGoogle Scholar
  144. Strömbom, U. (1976)Naunyn-Schmiedebergs Arch. Pharmacol. 292, 167–176;Ibidem (1977)J. Neural Transmission 40, 191–194.PubMedCrossRefGoogle Scholar
  145. Struyker Boudier, H. A. J., W. Gielen, A. R. Cools andJ. M. Van Rossum (1974)Arch. Intern. Pharmacodyn. 209, 324–333.Google Scholar
  146. Struyker Boudier, H. A. J., L. Teppema, A. R. Cools andJ. M. Van Rossum (1975)J. Pharm. Pharmacol. 27, 882–883.PubMedCrossRefGoogle Scholar
  147. Sumners, C., A. S. Horn, J. B. De Vries andD. Dijkstra (1980)Neurosci. Lett. (Suppl. 5), S 470.Google Scholar
  148. Sumners, C., J. B. De Vries, D. Dijkstra andA. S. Horn (1981)European J. Pharmacol. 70, 541–550.CrossRefGoogle Scholar
  149. Thal, L., I. Creese andS. H. Snyder (1978)European J. Pharmacol. 49, 295–299.CrossRefGoogle Scholar
  150. Titeler, M., andP. Seeman (1978)Experientia 34, 1490–1491;Ibidem (1979) In:The Neurobiology of Dopamine, 179–195.PubMedCrossRefGoogle Scholar
  151. Titeler, M., J. C. Tedesco andP. Seeman (1978a)Life Sci. 23, 587–592.PubMedCrossRefGoogle Scholar
  152. Titeler, M., P. Weinreich, D. Sinclair andP. Seeman (1978b)Proc. Natl. Acad. Sci. USA 75, 1153–1156.PubMedPubMedCentralCrossRefGoogle Scholar
  153. Titeler, M., S. List andP. Seeman (1979)Comm. in Psychopharmacol. 3, 411–420.Google Scholar
  154. Ungerstedt, U. (1971)Acta Physiol. Scand. Suppl. 367, 69–93.PubMedCrossRefGoogle Scholar
  155. Ungerstedt, U., T. Ljungberg andC. Ranje (1977) In:Psychobiology of the Striatum (Cools, A. R., A. H. M. Lohman andJ. H. L. van der Bercken, Eds.). Elsevier North Holland, Amsterdam, 85–97.Google Scholar
  156. Waddington, J. L., A. J. Cross, A. Longden, F. Owen andM. Poulter (1979)Neuropharmacology 18, 643–645.PubMedCrossRefGoogle Scholar
  157. Waggoner, W. G., J. Mcdermed andH. J. Leighton (1980)Mol. Pharmacol. 18, 91–99.PubMedGoogle Scholar
  158. Walters, J. R., andR. H. Roth (1976)Naunyn-Schmiedebergs Arch. Pharmacol. 296, 5–14.PubMedCrossRefGoogle Scholar
  159. Watling, K. J., J. E. Dowling andL. L. Iversen (1979)Nature 281, 578–580.PubMedCrossRefGoogle Scholar
  160. Weinreich, P., andP. Seeman (1980)Brain Res. 198, 491–496.PubMedCrossRefGoogle Scholar
  161. Westerink, B. H. C. (1979) In:The Neurobiology of Dopamine, 255–291.Google Scholar
  162. Westerink, B. H. C., andA. S. Horn (1979)European J. Pharmacol. 58, 39–48.CrossRefGoogle Scholar
  163. Westerink, B. H. C., andJ. Korf (1976a)European J. Pharmacol. 37, 249–255;Ibidem (1976b)40, 175–178.CrossRefGoogle Scholar
  164. Westfall, T. C., M. J. Besson, M. F. Giorguieff andJ. Glowinski (1976)Naunyn-Schmiedebergs Arch. Pharmacol. 292, 279–287.PubMedCrossRefGoogle Scholar
  165. Yamamura, H. I., S. J. Enna andM. J. Kuhar (Eds.) (1978)Neurotransmitter Receptor Binding. Raven Press, New York.Google Scholar
  166. Yeh, B. K., J. L. Macnay andL. I. Goldberg (1969)J. Pharmacol. Exp. Therap. 168, 303–309.Google Scholar
  167. York, D. H. (1979) In:The Neurobiology of Dopamine, 395–415.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1981

Authors and Affiliations

  • A. S. Horn
    • 1
  • M. G. P. Feenstra
    • 1
  • C. J. Grol
    • 1
  • H. Rollema
    • 1
  • J. C. Van Oene
    • 1
  • B. H. C. Westerink
    • 1
  1. 1.Department of PharmacyUniversity of GroningenAW GroningenThe Netherlands

Personalised recommendations